Collaboration and License Agreements - Additional Information 5 (Detail) (USD $)
|
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|---|
Sep. 30, 2014
|
Dec. 31, 2013
|
Oct. 31, 2010
Pfizer [Member]
Molecule
|
Sep. 30, 2013
Pfizer [Member]
|
Sep. 30, 2014
Pfizer [Member]
Program
|
Sep. 30, 2013
Pfizer [Member]
|
|
License And Collaboration Agreements [Line Items] | ||||||
Collaboration agreement date | October 2010 | |||||
Period of agreement | 3 years | |||||
Commercialization of molecules | 2 | |||||
Non-refundable upfront payment | $ 5,000,000 | |||||
Clinical milestone payments | 17,000,000 | |||||
Sales milestone payments | 195,000,000 | |||||
DART program | 1 | |||||
Research obligation completion date | 2014-01 | |||||
Recognized revenue under agreement | 900,000 | 3,200,000 | ||||
Deferred revenue | $ 15,617,000 | $ 20,267,000 | $ 0 |